Bevacizumab in recurrent ovarian cancer: could it be particularly effective in patients with clear cell carcinoma?
A GallegoJ Ramon-PatinoJ BrenesM MendiolaA BerjonG CasadoB CasteloE EspinosaA HernandezD HardissonJ FeliuAndres RedondoPublished in: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico (2020)
Adding bevacizumab to chemotherapy in recurrent CCC is associated with a remarkable benefit in this cohort. The efficacy of antiangiogenic drugs in CCC warrants further prospective evaluation.